Protara Therapeutics (TARA) launched a public offering of common shares.
Underwriters are expected to get a 30-day overallotment option for additional shares at the offering price, Protara said Monday in a statement.
Net proceeds are expected to fund the clinical development of TARA-002, among other things, the company said.
TARA-002 is an investigational cell therapy in development for the treatment of nonmuscle invasive bladder cancer and lymphatic malformations.
Protara's shares fell 8.7% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments